Gilead Beats US in Billion-Dollar Trial on Anti-HIV Patents (1)

Gilead Sciences Inc. won a closely watched patent trial against the federal government, which had sought $1 billion from the bioscience giant for allegedly using joint research to develop an HIV-prevention drug regimen without compensating the US.

A Delaware federal jury on Tuesday voided three government-owned patents at the heart of the case. It also ruled that Gilead’s Truvada and Descovy drugs wouldn’t have infringed the patents even if they were valid.

The case has been described as one of “exceptional interest” by some legal and industry observers. Columbia University law professor Christopher Morten previously told Bloomberg Law that the ...